ELLICOTT CITY, Md., June 16, 2011 /PRNewswire/ -- The network of clinical research sites affiliated with RxTrials, Inc., has expanded to Florida with the announcement of a new partnership with Tampa Bay Clinical Research Center.
Tampa Bay Clinical Research Center, based in Brandon, Fla., will specialize in pulmonary, critical care and sleep medicine studies. Principal investigators are Ivan Ackerman, MD, FCCP; Jonathan Axel, MD; and Divyang Sorathia, MD, all of whom are board certified and have clinical research experience. The Center features a full pulmonary function lab, staffed with pulmonary technicians, and a sleep study lab. Its extensive patient population is managed and accessed via the Center's electronic medical records system.
Michael Leon, RN, MBA, CCRC, has joined RxTrials as regional site manager to handle day-to-day operations of the new site. Leon, who has more than a decade of administrative experience in research site management, will work with the principal investigators and staff to ensure quality and delivery, and oversee study feasibility, budgeting and planning.
"As we look to grow our network of partner sites strategically, we seek sites that can adhere to our high standards for quality, professionalism and ethics," said Adam Chasse, RxTrials' vice president of business development. "Tampa Bay Clinical Research Center is an ideal addition and enables us to enhance our therapeutic capabilities in pulmonary, critical care and sleep medicine."
RxTrials, Inc. is a network of premier clinical research sites and parent company of RxTrials Institute, a leading national clinical research consultant and education provider. Since 1994, RxTrials has conducted more than 1,000 studies in a wide range of therapeutic areas. RxTrials Institute each year presents the Site Solutions Summit, a top networking and business management conference for clinical research sites, sponsors and CROs. The Summit takes place this year October 14 – 16 in Palm Beach Gardens, Florida (sitesolutionssummit.com).
SOURCE RxTrials, Inc.